UK markets close in 1 hour 29 minutes
  • FTSE 100

    6,908.19
    +12.90 (+0.19%)
     
  • FTSE 250

    22,254.61
    +168.88 (+0.76%)
     
  • AIM

    1,260.21
    +14.58 (+1.17%)
     
  • GBP/EUR

    1.1509
    -0.0062 (-0.53%)
     
  • GBP/USD

    1.3844
    -0.0088 (-0.63%)
     
  • BTC-GBP

    39,308.46
    -908.01 (-2.26%)
     
  • CMC Crypto 200

    1,267.60
    +24.55 (+1.97%)
     
  • S&P 500

    4,162.87
    -10.55 (-0.25%)
     
  • DOW

    34,002.61
    -134.70 (-0.39%)
     
  • CRUDE OIL

    61.21
    -0.14 (-0.23%)
     
  • GOLD FUTURES

    1,785.40
    -7.70 (-0.43%)
     
  • NIKKEI 225

    29,188.17
    +679.62 (+2.38%)
     
  • HANG SENG

    28,755.34
    +133.42 (+0.47%)
     
  • DAX

    15,257.64
    +61.67 (+0.41%)
     
  • CAC 40

    6,254.12
    +43.57 (+0.70%)
     

NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

NovaBay Pharmaceuticals (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market and CelleRx® Clinical Reset™ for the beauty market, announces that management will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference being held March 15-17, 2021.

Investors interested in arranging a meeting with NovaBay management should contact their Roth Capital Partners sales representative or LHA Investor Relations. The NovaBay corporate presentation can be access from the Investors section of the Company’s website here. Roth Conference information is available here.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Socialize and Stay informed on NovaBay’s progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website

Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com

CelleRx Clinical Reset Purchasing Information
For NovaBay CelleRx Clinical Reset purchasing information
Please call 877-CELLERX
www.CelleRx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005092/en/

Contacts

NovaBay Contact
Justin Hall
Chief Executive Officer and General Counsel
510-899-8800
jhall@novabay.com

Investor Contact
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com